ECKERT & ZIEGLER BG 
By Seneffe - Belgium, December 9, 2013. Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB) is pleased to announce that it is resuming production and distribution in its recently acquired manufacturing facility in Oxford, Connecticut (USA). Following delivery of individual products in the past few weeks, the full LDR brachytherapy portfolio, which includes the innovative core products AnchorSeed® and VariStrand(TM), is now once again available to American customers.
"Taking up production again at our new manufacturing facility in Connecticut marks a milestone in our company's history. We are pleased to announce that the remediation work has been completed successfully so we can once again supply our valued brachytherapy products 'Made in the USA' to the American market in the usual way," explained Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG.
Eckert & Ziegler BEBIG took over the business unit in Oxford from Biocompatibles with effect November 1, 2013. Biocompatibles had voluntarily suspended manufacture and delivery of its products in May 2013 after a warning letter from the FDA claiming shortcomings in its documentation of the manufacturing process.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with subsidiaries throughout Europe, in the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 200 people. The company has been listed on the NYSE Euronext stock exchange since April 1997.
Contact:
Claudia Wolf
Head of Marketing
Tel: +49 30 94 184 272
marketing@bebig.eu:
mailto:marketing@bebig.eu
Karolin Riehle
Investor Relations
Tel.: +32 (0) 64 520 808
ir@bebig.eu:
mailto:ir@bebig.eu
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Globenewswire
